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Abstract 45 
Preeclampsia (PE) is associated with increased cardiovascular long-term risk; 46 
however, the underlying functional and structural mechanisms are unknown. We 47 
investigated maternal cardiac alterations after PE. Female rats harboring the human 48 
angiotensinogen gene [TGR(hAogen)L1623] develop a preeclamptic phenotype with 49 
hypertension and albuminuria during pregnancy when mated with male rats bearing 50 
the human renin gene [TGR(hRen)L10J], but behave physiologically normal before 51 
and after pregnancy. Furthermore, rats were treated with pravastatin. We tested the 52 
hypothesis that statins are a potential therapeutic intervention to reduce cardiovascular 53 
alterations due to simulated preeclamptic pregnancy. Although hypertension persists 54 
for only 8 days in pregnancy, former PE rats exhibit significant cardiac hypertrophy 55 
28 days after pregnancy observed in both speckle tracking echocardiography and 56 
histological staining. In addition, fibrosis and capillary rarefaction was evident. 57 
Pravastatin treatment ameliorated the remodeling and improved cardiac output 58 
postpartum. Preeclamptic pregnancy induces irreversible structural changes of cardiac 59 
hypertrophy and fibrosis, which can be moderated by pravastatin treatment. This 60 
pathological cardiac remodeling might be involved in increased cardiovascular risk in 61 
later life.  62 
Key words: preeclampsia, pregnancy, cardiovascular risk, remodeling, pravastatin 63 
 64 
Introduction 65 
In 2011, the American Heart Association recognized pathological pregnancy, including 66 
gestational diabetes, preterm birth and preeclampsia as the first gender specific 67 
cardiovascular risk factor1. PE is a disorder with clinical symptoms in the last half of 68 
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pregnancy characterized by the onset of high blood pressure and signs of damage to 69 
another organ system (CNS with eclampsia, hematologic with thrombocytopenia), 70 
mostly relating to the liver and kidneys2. It was considered as a temporary condition as 71 
preeclamptic symptoms are generally resolved by placental birth. However, even if 72 
symptoms disappear, the higher risk for long-term renal and cardiovascular disease 73 
remains3. It is still unclear whether the increased risk is related to preeclamptic 74 
pregnancy or to predisposing factors, which already existed before pregnancy4. We 75 
have shown earlier that the mating of female Sprague-Dawley rats harboring the 76 
human angiotensinogen gene [TGR(hAogen)L1623] with [TGR(hRen)L10J] males 77 
leads to a preeclamptic phenotype with increased blood pressure starting on day 13 of 78 
pregnancy and albuminuria5, 6. In addition, fetal offspring are growth restricted6. The 79 
non-pregnant female [TGR(hAogen)L1623] rat show no noticeable phenotype, only 80 
when mated with  [TGR(hRen)L10J] males, both transgene products interact in the 81 
uteroplacental unit resulting in high Angiotensin II (Ang II) levels and inducing the 82 
preeclamptic phenotype6. 83 
Statins are crucial in the prevention and treatment of cardiovascular disease7. Besides 84 
the established cholesterol-lowering effect, pleiotropic effects including modulation of 85 
immune function and inflammatory processes as well as endothelial protection are 86 
important7. Currently the use of statins in pregnancy is not recommended; however, 87 
the topic is under intensive experimental and clinical research. In an initial case series 88 
a teratogenic risk was reported8, however, multiple recent meta-analysis failed to 89 
confirm this. Several potentially beneficial applications of statins in pregnant women, 90 
including PE9 and anti-phosholipdantibody syndrome warrant further evaluation10. 91 
From all the different statins, pravastatin is most suitable for the application in 92 
pregnancy due to its unique pharmacokinetic and physiochemical properties. 93 
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Pravastatin has a limited ability to cross the placenta and is known to be one of the 94 
most hepatoselective and hydrophilic (polar) statins11. Thus, pravastatin has been 95 
shown to improve maternal and fetal impacts of PE in multiple mouse models12, 13 as 96 
well as in human pilot studies9, 10. Furthermore, it is known that statins have various 97 
protective effects in the cardiovascular system7. We tested the hypothesis that 98 
pravastatin has a beneficial effect on the remodeling of the maternal heart after 99 
preeclamptic pregnancy and therefore lowers the long-term cardiovascular risk. 100 
 101 
Methods 102 
The authors declare that all supporting data are available within the article (and its 103 
online supplementary files). 104 
Animals: 12-week-old virgin female Sprague-Dawley rats harboring the human 105 
angiotensinogen gene [TGR(hAogen)L1623] were mated with male rats bearing the 106 
human renin gene [TGR(hRen)L10J]. Daily, females were inspected for vaginal plugs. 107 
The first day that a plug was noticed was termed as first day (d1) of pregnancy. 108 
Pregnant transgenic rats developed typical preeclamptic phenotype with hypertension 109 
starting on d13 and albuminuria in later pregnancy5. Rats were housed in a 110 
temperature-controlled environment of 22+/-2°C, a humidity of 55+/-15% and 12:12-111 
hour light/dark cycle. The animals had access to food (Sniff V1324-300) and water ad 112 
libitum. Rats were sacrificed at the end of pregnancy (d21) and 28 days postpartum by 113 
decapitation with prior isoflurane anesthesia or due to predefined stopping criteria 114 
according with the European law for animal protection. Local authorities approved the 115 
studies (State Office of Health and Social Affairs Berlin). 116 
Experimental design: [TGR(hAogen)L1623] female rats impregnated by 117 
[TGR(hRen)L10J] form the preeclamptic group (PE). Age- and body weight-matched 118 
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wild-type Sprague-Dawley rats constituted the control group (WT). For potential 119 
intervention, one group of PE rats were treated daily with pravastatin (5 mg/kg/day, 120 
Sigma Aldrich)14 via drinking water until 28 days postpartum (PE pp + prava) which is 121 
equivalent to two years of life in human15. Treatment started on day 15 of gestation. 122 
WT + prava was not included in the study because of the low clinical need. 123 
Blood pressure measurement: DSI telemetry devices (DSI, HD-T11) for blood pressure 124 
monitoring were implanted 14 days before mating as described before6. 125 
Measurements were taken before, at the end of pregnancy (d21) and 28 days 126 
postpartum in a 5-minute distance.  127 
Echocardiography: Transthoracic echocardiography was performed in anesthetized 128 
animals (1.5% isoflurane via an oxygen mask) at the end of pregnancy (d21) and 28 129 
days postpartum. ECG, respiration and temperature were monitored. Rectal 130 
temperature was maintained at 36°C by heated platform. All of the hair was removed 131 
from the abdomen by depilatory cream and pre-warmed gel was used as an 132 
ultrasound-coupling medium. A Vevo 3100 high-resolution imaging system (Fujifilm, 133 
VisualSonics Inc.) with a 21 MHz transducer (MS250) mounted on an integrated rail 134 
system was used. All images were acquired and stored for offline analysis by blinded 135 
observer using VisualSonics VevoStrain software (Version 2.2.0, Toronto, Canada). B-136 
Mode cine loops were used in parasternal long and short axis view to assess basic 137 
parameters for systolic function and more sensitive speckle tracking analysis. Images 138 
were checked for quality with regard to differentiation of wall borders and absence of 139 
artefacts. The endocardium of the left ventricle was traced manually in parasternal 140 
short- and long-axis views in end-diastole. Analysis was performed on three 141 
consecutive cardiac cycles; mean values from three measurements were calculated. 142 
Global strain values were obtained from the average of the six segments of the left 143 
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ventricle. M-mode was obtained to measure cardiac wall and chamber dimensions. 144 
Relative wall thickness was calculated by the formula (2*PWd)/LVEDD.  145 
mRNA isolation and qRT-PCR: Snap frozen cardiac tissue of the left ventricle was 146 
homogenized by ceramic beads. Total RNA was extracted using commercial Kits (lysis 147 
reagent and RNeasy mini kit, Qiagen) and protocols provided by the manufacturers. 2 148 
μg of mRNA was reverse transcribed into cDNA using High Capacity cDNA Reverse 149 
Transcription Kit (Applied Biosystems). Relative quantification of gene expression was 150 
performed by real-time polymerase chain reaction (PCR) using an ABI 7500 Fast 151 
Sequence Detection System (Applied Biosystems) and analyzed by 7500 Fast System 152 
Software (Applied Biosystems). Primers and probes (Supplementary Table S1) were 153 
designed with Primer Express 3.0 (Applied Biosystems) and synthesized by Biotez, 154 
Germany. Quantitative analysis of target mRNA expression was performed with real-155 
time PCR using the relative standard curve method. 36B4 was used as housekeeping 156 
gene. The primer for all target were validated by blasting. 157 
Circulatory and urinary factors: The expression of circulating BNP and sFlt1 was 158 
analysed in venous blood plasma by using ELISA kits (#ab108816 BNP45, abcam: 159 
#MBS725733 sFlt1, MyBioSouce). Urinary albumin was detected by the company 160 
CellTrend, Luckenwalde Germany.  161 
Immunohistochemistry: Hearts were harvested, fixed with formalin and embedded in 162 
paraffin. Samples were cut through the short axis into 2 µm thick sections and stained 163 
with antibodies for wheat germ agglutinin (WGA, #FL-1021 Vector Laboratories), 164 
collagen type I (#1310-01, SouthernBiotech), fibronectin (#ab23751, abcam), CD68 165 
(#MCA341R, Bio-Rad) and CD31 (#AF3628, R&D) followed by Cy3-labeled secondary 166 
antibody to detect cardiac remodeling. Vectashield mounting medium with DAPI (#H-167 
1200, Vector Laboratories) was used to stain nuclei. The stained sections were imaged 168 
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by fluorescence slide scanner Pannoramic MIDI II BF/FL high speed (3DHISTECH 169 
Ltd., Budapest, Hungary), saved and offline evaluated using CaseViewer analysis 170 
software (3DHISTECH Ltd., Budapest, Hungary). To quantify the perimeter of 171 
cardiomyocytes, 100 randomly selected cells per section were framed manually in 172 
WGA staining. Collagen type I staining was used to determine the content of 173 
perivascular fibrosis. All vessels were assessed with regard to internal diameter, media 174 
and fibrotic boarder. Fibrotic area in relation to media area was compared. To quantify 175 
interstitial fibrosis, 16 representative microscope fields per section without vascular 176 
content were determined with regard to percentage of fibrosis (fibronectin staining) 177 
using ImageJ (NIH). CD68 staining was applied to clarify inflammation status. 20 178 
representative microscope fields per section without vascular content were manually 179 
counted for positive cells. To clarify capillary density in the hearts, CD31 staining of 180 
endothelial cells was exerted16. 10 representative microscope fields per section were 181 
manually counted for positive signals. For all staining, mean score for each animal was 182 
calculated by blinded observer and used to deduce a group mean score. To test 183 
specific binding sites negative controls were used without primary antibody to make 184 
sure that the secondary antibody do not bind unspecific. No isotype control was used. 185 
Statistics: Statistical analyses were performed by using Prism 7.0 software (GraphPad 186 
Software Inc.). ROUT method was performed for outlier identification with an average 187 
false discovery rate less than 1%. P < 0.05 was considered statistically significant. 188 
After testing for normal distribution group differences were analyzed by 2-tailed 189 
unpaired t test, Mann-Whitney U test, one-way ANOVA with Tukey post hoc test for 190 
multiple comparison or 2-way ANOVA with Bonferroni post hoc test, as appropriate. 191 
All data is presented as means±SD. 192 
 193 
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Results  194 
Evaluation of cardiac function by Speckle Tracking Echocardiography (STE) 195 
Detailed echocardiography including STE was performed to evaluate alterations in 196 
cardiac function (Tab. 1). Ejection fraction is mildly but significantly decreased 197 
postpartum in the PE rats, but remains within normal limits. In these rats, an increase 198 
in heartrate is also observed. Left ventricular mass is more than 10 % higher in former 199 
PE rats compared to wild-type controls (WT pp) and goes closely together with an 200 
increased posterior wall thickness and a higher relative wall thickness. Values of inner 201 
diameter are unaltered. Pravastatin treatment (PE pp + prava) improves the mentioned 202 
parameter, but not completely to the level of unaffected control pregnancy. Global 203 
longitudinal strain, global radial strain, and global circumferential strain are significantly 204 
reduced postpartum in the PE rats. Similar results are observed for the corresponding 205 
global strain rates. Former preeclamptic rats who were treated with statins 206 
demonstrate better values than untreated ones. The detected echocardiographic 207 
changes are already partly seen at the end of pregnancy (data not shown), but 208 
becoming more pronounced postpartum. Figure 1 summarizes the relative postpartum 209 
changes due to a preeclampsia simulating pregnancy and the benefits of statin 210 
treatment. As previously published, blood pressure and proteinuria are increased 211 
during pregnancy in this transgenic rat model for PE6. We confirm higher mean arterial 212 
pressure (MAP) in the PE rats on day 18 of pregnancy, independent of statin treatment 213 
(Suppl. Fig. S1A-B). Importantly, no differences in MAP are observed postpartum 214 
(Suppl. Fig. S1C-D). Increased levels of urinary albumin are detected during PE and 215 
could be reduced by pravastatin (data not shown).  216 
 217 
Pathological cardiac remodeling  218 
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Replacement fibrosis in the myocardium is the hallmark of myocardial remodeling, 219 
which can be found in pathological hypertrophy17. Hearts after a preeclamptic 220 
pregnancy (PE pp) show larger cardiomyocytes. This enlargement can be avoided by 221 
pravastatin (Fig. 2A). Immunohistochemical studies show increased levels of 222 
fibronectin postpartum. Pravastatin can reduce this interstitial fibrosis (Fig. 2B). In 223 
addition, we detect fibrotic spots in 7 out of 11 preeclamptic hearts postpartum. Hearts 224 
in the control group were unaffected. Treated PE rats show these spots only in 3 out 225 
of 9 hearts (supplemental Fig. S2A). In addition, preeclamptic hearts also show a 226 
higher perivascular fibrosis compared to controls postpartum (Fig. 2C). Postpartum is 227 
no difference in CD68-positive cells noticed (Fig. 2D). Inflammation in maternal hearts 228 
is only detectable during PE by a higher number of CD68-positive cells (ED1 staining). 229 
Treatment with pravastatin reduces the number of macrophages (Suppl. Fig. S2B). To 230 
test the additional hypothesis that microvascular damage is sustained during 231 
preeclamptic pregnancy, we compare capillary density. Hearts of PE rats show a lower 232 
number of capillaries. This rarefaction could be avoided by pravastatin (Fig. 2E).  233 
Brain natriuretic peptide (BNP) is still increased in blood plasma levels in PE rats pp. 234 
Animals treated with pravastatin show no increase compared to wild-type controls (Fig. 235 
3A). This is already detectable during pregnancy (Suppl. Fig. S3A). Soluble fms-like 236 
tyrosine kinase-1 (sFlt1) is a protein with antiangiogenic properties and is used as one 237 
of the first biomarker for PE18. With increased binding affinity to the vascular endothelial 238 
growth factor (VEGF), sFlt1 reduces blood vessel growth19. Preeclamptic animals 239 
show increased levels of blood sFlt1 not only at the end of pregnancy (Suppl. Fig. 3B), 240 
but also postpartum this factor is still increased. Pravastatin treatment reduces levels 241 
of sFlt-1 (Fig. 3B). Treated groups show no increase in sFlt-1 compared to wild-type 242 
controls. 243 
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 244 
Alteration of gene expression levels 245 
Predominantly at the end of pregnancy but also postpartum, we could detect altered 246 
gene expression related to hypertrophy, fibrotic remodeling, inflammation and 247 
disturbed angiogenesis (Fig. 4). Four weeks after delivery most dysregulated genes 248 
are comparable to controls. PE rats show higher levels of atrial natriuretic protein (Anp) 249 
and a borderline significant increase in Bnp. Fibrotic marker genes like fibronectin (Fn) 250 
or collagen type I (Col1) are also increased in PE rats. Matrix metallopeptidase 2 251 
(Mmp2) shows no difference. Connective tissue growth factor (Ctgf) is only elevated 252 
postpartum, with no effect of treatment. Tissue growth factor β (Tgf β), tumor necrosis 253 
factor α (Tnf α) and interleukin-6 (Il-6) are not changed. Monocyte chemoattractant 254 
protein 1 (Mcp1) and the cluster of differentiation 68 (CD68), as well as lipocalin (Ngal) 255 
are increased during PE. The CCAAT/enhancer binding protein β (Cebpb) is 256 
unchanged and the genes for myosin heavy chain α (Myh 6) and β (Myh 7) only reach 257 
borderline significance. The Angiotensin II receptor type 1 (At-1), Phospholamban (Pln) 258 
and the hypoxia inducible factor 1 (Hif1) are reduced in preeclamptic animals during 259 
pregnancy. The sFlt-1 is not altered in heart tissue. Matrix metallopeptidase 12 260 
(Mmp12) is highly upregulated in PE rats. These changes could be improved by statins 261 
and do not persist. Postpartum persistent and unaffected by treatment is the 262 
expression of endothelin-1 (Et-1) and platelet endothelial cell adhesion molecule 263 
(Pecam-1). Vascular endothelial growth factor A (Vegfa) and matrix metallopeptidase 9 264 
(Mmp9) seem downregulated. The Rho associated coiled-coil containing protein 265 
kinase 1 (Rock1) is reduced during PE and higher expressed when the animals are 266 
treated. Total values of gene expression are given in supplemental table S3. 267 
 268 
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Safety of fetal outcome 269 
Pravastatin did not influence the numbers of fetuses, implantations and resorptions in 270 
regard to untreated PE rats or WT controls (Suppl. Fig. 4A-C). PE offspring often suffer 271 
from placental insufficiency and growth restriction20. Pravastatin show no negative 272 
effect in weight of the uteroplacental unit (Fig. 5A) or weight the fetus (Fig. 5B). Fetal 273 
heart weight (Fig. 5C), heart body ratio (Fig. 5D), brain liver ratio (Fig. 5E) or fetal 274 
kidney weight (Fig. 5F) are not altered.  275 
 276 
Discussion  277 
The major finding in our study is that PE leads to persistent structural remodeling and 278 
functional changes in the maternal heart, which can be attenuated by pravastatin 279 
treatment. The effect of pravastatin was independent of blood pressure. Cardiac 280 
hypertrophy and fibrosis were present during PE and persisted postpartum. Interstitial 281 
fibrosis is regarded as replacement fibrosis and we speculate that this process might 282 
be persistent. Hypertrophy and fibrosis are major causes for the observed diastolic 283 
dysfunction, described by several parameters in the echocardiographic data. In 284 
addition, we used speckle tracking analysis to analyze the degree of myocardial 285 
deformation and to detect even subclinical changes already described in humans21. 286 
Preeclampsia is not a mono-causal disease as it is in the used animal model. However, 287 
the transgenic animal model resembles many important features of the human 288 
syndrome, such as placenta induced pathology22 with high blood pressure, proteinuria 289 
and IUGR6, increased sFlt-1 levels23 or existing AT1 auto-antibodies24. Furthermore 290 
the female is healthy before pregnancy and blood pressure resolves after delivery. We 291 
hypothesize that the observed findings leading to heart failure stage B are 292 
pathophysiological mechanisms leading to the observed significantly higher risk for 293 
 13 
 
long-term cardiovascular disease in these patients. Women with PE and their offspring3 294 
have an increased risk for later cardiovascular disease (CVD). Two theories speculate 295 
about the causality that link PE and CVD. The first is that PE and atherosclerosis share 296 
risk factors for systemic inflammation and endothelial dysfunction, which are 297 
unmasked by the “stress” of pregnancy25. It is also possible that pregnancy, and 298 
especially PE, may induce permanent arterial changes, mediating risk for future CVD 299 
through the pro-atherogenic stress of PE that could activate arterial wall inflammation 300 
that fails to resolve after delivery. 301 
The effect of PE on the cardiovascular microvasculature is striking. A large number of 302 
human studies have documented that healthy women with a history of PE have 303 
elevated vasoconstrictor responses26, increased arterial stiffness27 and show retinal 304 
microvascular dysfunction28. This goes closely together with our findings regarding 305 
rarefaction of myocardial capillaries and might be the cause for healthy former 306 
preeclamptic women having an increased long-term risk for cardiovascular disease. 307 
Statins are able to ameliorate the decrease in capillary density in the heart shown in a 308 
study with pigs29. Paulus et al. recently introduced a novel concept for heart failure with 309 
preserved ejection fraction30. They propose that the cause of myocardial structural and 310 
functional alterations is a systemic pro-inflammatory state leading to microvascular 311 
endothelial dysfunction. We already could show that the cardiovascular biomarker 312 
midregional proatrial natriuretic peptide (MR-proANP) could also be a suitable marker 313 
for PE and speculated that it reflects a cardiovascular hemodynamic stress31. There is 314 
an increasing understanding that CVDs are generally progressive disorders that 315 
proceed through asymptomatic to symptomatic stages32. Women are much more likely 316 
to suffer from Ischemia and Non Obstructive Coronary Artery Disease (INOCA)33. 317 
These patients have elevated risk for a cardiovascular event and appear to be at higher 318 
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risk for the development of heart failure with preserved ejection fraction. It is 319 
remarkable that the preeclamptic phenotype which lasts in the animal model for only 8 320 
days has such a profound long-term effect. Recently a novel concept has been 321 
proposed indicating that the pathological remodeling process induced by cardiac 322 
stressors such as angiotensin II (Ang II) depends on the context and condition of the 323 
organism. Ang II induces dramatic vasoconstriction, collapse and regression of 324 
immature capillaries in the developing organ of 8 weeks old mice, whereas in an adult 325 
mouse the same dosage has a far less profound effect on the retinal vasculature34. We 326 
speculate that pregnancy, with its pro-inflammatory milieu and the extraordinary 327 
metabolic demands and cardiovascular adaptation, represents a potentially unstable 328 
situation where cardiac stressors such as Ang II or preeclamptic mediators, such as 329 
sFlt1 or activating autoantibodies against the AT1 receptor are capable of inducing 330 
long-term cardiovascular consequences. 331 
At the moment, the only “cure” for PE is delivery. Treatment during pregnancy to 332 
improve maternal and fetal outcome is limited. Methyldopa or nifedipine, the drugs of 333 
first choice, lower blood pressure and help to extend wearing time35. However, no 334 
treatment has yet been shown to reduce long-term cardiovascular risk in preeclamptic 335 
patients. The beneficial effect of pravastatin treatment is described by enhanced 336 
cardiac function, less cardiac hypertrophy and diminished cardiac fibrosis. Even if there 337 
was no change in systolic blood pressure, our results indicate a reduction in structural 338 
remodeling which goes hand in hand with an improvement in cardiac function. 339 
Reversion of fibrosis in the heart by statins was shown in other disease models 340 
before36, 37. Hermida et al. demonstrated that statin treatment reverses myocardial 341 
remodeling and improves ventricular relaxation through AMPK-mediated anti-fibrotic 342 
effects37. Another study showed that simvastatin inhibited the fibrosis around coronary 343 
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arteries in endogenous adrenomedullin heterozygous knockout mice treated with 344 
angiotensin (Ang) II and high salt loading36. Taken together, pravastatin attenuates 345 
hypertrophic and pro-fibrotic stimuli and thereby reduces the long-term risk of 346 
cardiovascular diseases after preeclamptic pregnancy. All positive effects seen by 347 
pravastatin were cholesterol-independent due to the fact that statins do not lower 348 
serum cholesterol in rats because of compensatory increases in hepatic enzyme 349 
production38. Similar to the findings of Garrett et al.12 and Bauer et al.39, we postulate 350 
a beneficial impact of pravastatin treatment with no detectable harm to the fetal 351 
outcome. In comparison with other disease models40 which need much more duration 352 
of high blood pressure than this short period during pregnancy, the advantageous 353 
effect of pravastatin could be explained. Mice exposed to Ang II overexpression for 354 
four weeks, developed high blood pressure in combination with cardiac hypertrophy 355 
and fibrosis40. Daily treatment with pravastatin had no effect on systolic blood pressure 356 
but improved cardiac function and reduced left ventricular hypertrophy and fibrosis. 357 
Pleiotropic effects of statins restored endothelial function and decreased vascular 358 
inflammation. Many of these effects are mediated by the localization and function of 359 
intracellular signaling molecules like small GTP-binding proteins, Rho, Ras and Rac41.  360 
We showed that Rock1 which is the intermediate downstream target of RhoA is 361 
dysregulated in the heart in preeclamptic rats at the end of pregnancy compared to 362 
control rats. Pravastatin ameliorates the downregulation of Rock1. For this reason, the 363 
pathway of Rho-kinase seems to have a crucial influence on the effects of pravastatin 364 
in lowering long-term cardiovascular risk after preeclampsia42. Additionally, it was 365 
shown in Hemoxygenase 1 deficient mice that pravastatin increases HO-1 activity in 366 
liver and placenta and improves survival of the fetus43.  367 
Perspectives  368 
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Preeclampsia currently has no effective pharmacological treatment to reduce long-369 
term cardiovascular risk. In the transgenic rat model with preeclampsia-like symptoms, 370 
we found that pravastatin has a high potential to benefit maternal outcome with no 371 
harm to the offspring. Statins have a well-established role in the prevention of 372 
cardiovascular disease in general population44 and there are counting indications that 373 
statins may have similar cardiovascular gain in preeclampsia45. Indeed, a human pilot 374 
study detected no identifiable safety risk9.  375 
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 541 
Novelty and Significance 542 
What Is New? 543 
- PE leads to persistent structural remodeling of the heart 544 
- Preeclamptic mothers may benefit from pravastatin treatment to prevent cardiac 545 
changes 546 
- Pravastatin treatment in the last trimester does not harm the fetus of a 547 
preeclamptic pregnancy  548 
What Is Relevant? 549 
PE leads to increased cardiovascular long-term risk¸ however, the underlying 550 
functional and structural mechanisms are unknown. The present study investigated 551 
persistent structural alterations as presumed cause and showed the benefit of statin 552 
treatment for maternal long-term health. 553 
Summary: 554 
With advanced echocardiography we demonstrate alterations in the transgenic rat 555 
model for simulated preeclampsia. Former preeclamptic rats exhibit significant cardiac 556 
hypertrophy postpartum in combination with fibrosis and capillary rarefaction. 557 
Pravastatin treatment ameliorated the remodeling and improved cardiac output 558 
postpartum.  559 
  560 
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Figure Legends 561 
Table 1. Functional and structural changes after PE were detected by advanced 562 
echocardiography and improved by statin treatment. Data shown as mean±SD; WT 563 
n=8, PE n=10, PE+prava n=7; pp postpartum, LV left ventricle; One-way ANOVA, * 564 
significant to WT, # significant to PE. 565 
Figure 1. Pravastatin improves cardiovascular dysfunction. Relative values of treated 566 
and untreated preeclamptic animals in comparison to the healthy wild-type group are 567 
shown. Healthy controls were normalized to 1. Pp postpartum.   568 
Figure 2. Preeclampsia led to persistent hypertrophy, increased fibrosis and capillary 569 
rarefaction. Cardiac hypertrophy (A), interstitial (B) and perivascular fibrosis (C), CD68-570 
positive cells (D) and cardiac capillaries (E) are shown. Data shown as mean±SD; WT 571 
n=8, PE n=8, PE +prava n=8; pp postpartum; Scale WGA 20µm, Fn 50µm, Col1 50µm, 572 
CD31 20µm, ED1 20µm. One-way ANOVA, ns. not significant, ***p<0.001, 573 
****p<0.0001. 574 
Figure 3. Pravastatin reduced persistent elevation of plasma BNP and sFlt1 levels 575 
after preeclamptic pregnancy. Levels of brain natriuretic peptide (A) and soluble fms-576 
like tyrosine kinase-1 (B) are shown. Data shown as mean±SD; WT n=6, PE n=7, PE 577 
+prava n=6; pp postpartum; One-way ANOVA, *p<0.05, **p<0.01, ***p<0.001. 578 
Figure 4. Alterations in gene expression levels were detectable predominantly at the 579 
end of PE. Heat maps of gene expression levels during pregnancy and postpartum. 580 
Data given as median. Total values are given in Tab. S2. WT d21 n=6, PE d21 n=5, 581 
PE d21 +prava n=5, WT pp n=8, PE pp n=8, PE pp +prava n=8; d21 day 21 of 582 
pregnancy, pp postpartum; One-way ANOVA *p<0.05, **p<0.01, ***p<0.001, 583 
****p<0.0001, #p<0.05 significant to PE. 584 
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Figure 5. Pravastatin has no harmful effect on the offspring. Placental weight (A), fetal 585 
body weight (B) and heart weight (C), as well as fetal heart body ratio (D), fetal brain 586 
liver ratio (E) and fetal kidney weight (F) are shown. Data shown as mean±SD; mean 587 
values per dam are shown; WT n=3, PE n=7, PE + prava n=7; One-way ANOVA, ns. 588 
not significant, *p<0.05, **p<0.01, ***p<0.01, ****p<0.0001. 589 
